Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.

 

  • There remains a global shortage of vaccines to prevent COVID-19 and licensing new vaccines could help fill the gap.
  • Researchers identify average antibody levels (called ‘correlates of protection’) required to prevent COVID-19 in populations.
  • Correlates of protection could be used to extrapolate efficacy from trials of new vaccines, and could speed development.

Using an analysis based on COVID-19 cases detected in the United Kingdom, and immune system data from the blood samples of volunteers who took part in the UK trials of the Oxford vaccine, the researchers compare antibody levels in vaccine recipients 28 days after their second dose, and COVID-19 cases that occurred more than 7 days after the blood sample was taken.

Writing on MedRxiv, they report that higher levels of anti-spike, anti-RBD IgG, and neutralising antibody titres were associated with a greater degree of protection against COVID-19 – defined as a PCR positive test with at least one symptom present.

Read the full story on the University of Oxford website

Similar stories

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.